Pharmacy Law Update — Oklahoma Board of Pharmacy requirements for pharmacies and prescribers
Customize your policy alerts
Sign up for all healthchoiceoklahoma policy alerts
Know when healthchoiceoklahoma releases new policies or updates existing guidance.
Monitor payer policy activity
Summarizes changes and current Oklahoma Board of Pharmacy requirements affecting pharmacy practice, immunizations, compounding, sterile and non-sterile processes, technician roles, vaccine storage, prescription delivery, and Prescription Monitoring Program (PMP) obligations for prescribers. Affects Oklahoma-licensed pharmacies, pharmacists, prescribers, and pharmacy interns.
No material clinical or coverage changes in this revision.
Coverage Criteria & Compounding Restrictions
Sterile compounding for office-use is prohibited in Oklahoma; pharmacies performing sterile preparations must hold a current sterile compounding permit and comply with applicable USP standards (for example, USP 797). Compounding that is allowed in the pharmacy must be patient-specific (dispensed only pursuant to a patient-specific prescription) unless the product is supplied by a registered 503(b) outsourcing facility that meets FDA and CGMP requirements.
Sterile preparations that require a permit include, but are not limited to, injectables, irrigation solutions, inhalation solutions, and ophthalmics. Non-sterile office-use compounding may be permitted under Oklahoma rules, but sterile office-use compounding is expressly not allowed.
Pharmacies that perform sterile compounding must maintain required records and quality controls including documented intern training, cleaning logs and schedules (work area cleaning each shift/prior to each batch/after spills/every 30 minutes when in continuous use/when contamination is suspected; counters, work surfaces, and floors daily; walls, ceilings, and shelving monthly), and an equipment calibration log. Records must document acquisition of FDA-approved drug components purchased from OSBP-licensed entities. Failure to maintain these permits, logs, calibration records, and compliance with USP standards may subject the registrant to regulatory enforcement.
Deliveries of patient-specific filled prescriptions must be made to a location where they will be administered; permanent office-use sterile stock or distribution intended for office inventory is not permitted under Oklahoma law.
Site-of-care delivery and prohibition on sterile office‑use products
Deliver patient-specific filled prescriptions only to a location where they will be administered; do not dispense sterile products for office-use (sterile office‑use compounding is prohibited).
- Patient-specific filled prescriptions must be delivered to the location where they will be administered.
- Sterile office-use compounding is not permitted; sterile preparations require a sterile compounding permit and compliance with USP standards.
Required Provider Actions & Documentation
No prior authorization specified
This document does not impose any prior authorization requirements.
Naloxone distribution method
Naloxone may be distributed either by physician protocol or by patient-specific prescription; it must not be sold over-the-counter (NOT OTC).
Refill authorization workflow
A pharmacy technician may accept a refill authorization from the prescriber's office when no changes are made to a non-controlled (non-CDS) prescription. A pharmacist must accept refill authorizations when changes are made to a non-CDS prescription and must accept refill authorizations for any controlled substance (CDS) prescription.
Mid-level practitioner prescribing limits
Physician assistants (PAs) and advanced practice registered nurses (ARNPs) must be licensed in Oklahoma and supervised by an Oklahoma-licensed physician; out-of-state PAs and ARNPs are not permitted. Supply limits apply for CDS III–V (e.g., PA: up to 30 days, no refills; APRN: original plus refills totaling up to 30 days).
Required records for compounding
Maintain sterile compounding records including cleaning logs, a cleaning schedule, equipment calibration logs, records of FDA‑approved drugs purchased from OSBP‑licensed entities, intern training documentation, and BUD justification when extending beyond standard limits.
- Cleaning logs and cleaning schedule (work area each shift/prior to each batch/after spills/every 30 minutes when in continuous use; counters daily; walls/ceilings monthly)
- Equipment calibration log
- Records of FDA-approved drugs purchased from OSBP‑licensed entities
- Intern training documentation
- BUD extension supported by scientific data
Loss reporting and record retention
When reporting significant loss/theft, retain a copy of the DEA Form 106 report; sending copies to OBNDD and OSBP is advised and keep a copy for your records.
- Use electronic DEA 106 (link on OSBP site)
- Send copy to OBNDD (419 NE 38th Terrace OKC, OK 73105)
- Send copy to OSBP (2920 Lincoln Blvd, Ste A OKC, OK 73105)
Sterile compounding compliance risk
Failure to maintain required sterile compounding permits, records, cleaning logs, equipment calibration logs, and compliance with applicable USP standards may result in regulatory action.
PMP check documentation interval
Prescribers must document prescription monitoring program (PMP) checks in the patient's chart for applicable controlled or specified medications at least every 180 days.
Document PMP query in chart
Prescribers are required to document in the patient's chart that the PMP was checked for applicable patients receiving opiates, carisoprodol, or benzodiazepines.
Enforcement risk for PMP noncompliance
Prescribers who do not check and document the PMP every 180 days for patients receiving opiates, carisoprodol, or benzodiazepines risk enforcement action by their licensing board.
Enforcement risk for missing PMP queries
Failure to query the PMP for new patients or for existing patients every 180 days when prescribing opiates, carisoprodol, or benzodiazepines may result in enforcement by the prescriber's licensing board.
Where Medications May Be Delivered or Dispensed
Delivery location and sterile office-use restriction
Deliveries of patient-specific filled prescriptions must be made to a location where they will be administered; sterile office-use products may no longer be compounded for office use.
Entity (school/business) prescriptions allowed
Prescriptions written to an entity (e.g., schools or businesses) may be dispensed to that entity; an appropriate quantity may be filled each time (example: epinephrine prescribed for an entity for up to 24 doses).
- Prescriber writes prescription for the entity (e.g., YMCA) for epinephrine #24
- Pharmacy may fill under the entity name and dispense/refill as directed by the prescriber
- Prescriber is responsible to ensure the entity has policies and procedures for proper usage
Quantity Limits and Specific Drug Limits
Key Definitions and Dates
Background & Scope Summary
This presentation summarizes Oklahoma Board of Pharmacy operational and regulatory requirements relevant to pharmacies providing immunizations, compounding, and routine dispensing. Key operational topics include permitted versus prohibited compounding practices, requirements for a licensed pharmacist-in-charge and sterile compounding permits, and expectations to meet applicable USP standards.
For compounding specifically, the Board emphasizes that sterile compounding requires a permit and adherence to USP standards; pharmacies must maintain documented cleaning schedules and logs (work area cleaning each shift/prior to batches/after spills/periodically during continuous use, daily surface cleaning, monthly walls/ceilings/shelving), equipment calibration logs, intern training documentation, and records of FDA-approved drugs acquired from OSBP-licensed entities. These operational and documentation requirements support compliance and reduce regulatory risk.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.